Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

1(20%)

Results Posted

0%(0 trials)

Terminated

2(40%)

Phase Distribution

Ph phase_1

20%

Ph phase_2

60%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(2)

Other(1)

Detailed Status

Terminated2

Completed1

Recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

completed120%

recruiting120%

terminated240%

unknown120%

Recent Activity

1 active trials

Showing 5 of 5

terminatedphase_1

Liver Cell Transplant for Phenylketonuria

NCT01465100

recruiting

Incidence, Course and Outcome of ABMR in Kidney Transplantation

NCT05140018

terminatedphase_2

Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

NCT01582048

completedphase_2

Induction of Stable Chimerism for Sickle Cell Anemia

NCT00029393

unknownphase_2

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

NCT01786018

Clinical Trials (5)

Showing 5 of 5 trials

NCT01465100Phase 1

Liver Cell Transplant for Phenylketonuria

Terminated

NCT05140018

Incidence, Course and Outcome of ABMR in Kidney Transplantation

Recruiting

NCT01582048Phase 2

Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

Terminated

NCT00029393Phase 2

Induction of Stable Chimerism for Sickle Cell Anemia

Completed

NCT01786018Phase 2

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

Unknown

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5